CORT·Corcept Therapeutics Incorporated
CORT|Analyst Targets
CORT|Insider Trading
CORT|Fundamentals
CORT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.86 | - | - |
| Q3'25 | $0.14 | $0.16 | +18.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $343M | - | - |
| Q3'25 | - | $208M | - |
CORT|Monthly Returns
Market Data
CORT Stock Snapshot
- Market cap
- 13.12B
- P/E ratio
- 237.8
- Day range
- $117.42 – $122.81
- News sentiment
- 48/100 · Neutral
- Analyst target
- $141.00 (+19.9%)
- Consensus
- Buy · 13 analysts
Neither side has the upper hand on CORT right now, and its momentum ranks near the middle of DailyIQ's universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What CORT's own history says about today's numbers
- Realized volatility (21d)
- 36.0% 21st pct
- Below its peak
- -2.3%
- vs 200-day average
- +71.1%
- Up days (1y)
- 53%
Corcept Therapeutics Incorporated is currently running 36.0% annualised volatility over the last 21 sessions. Measured against CORT's own 13 years of daily returns rather than a market-wide average, that is the 21st percentile — unusually subdued by its own history, against a typical reading of 49.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
CORT is trading -2.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.3%, and the deepest was -62.5% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +71.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year CORT closed higher on 53% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, CORT finished the month higher 7 of 13 times, with a median return of +0.6% and an average of +1.1%. Its strongest month historically has been March at +10.1% on average, its weakest December at -6.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: CORT has opened more than 2% away from the prior close in 346 of 3,264 sessions (10.6% of the time), with the largest gaps running +17.2% and -32.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,266 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against CORT's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CORT's sector?
Corcept Therapeutics Incorporated sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, CORT ranks 13th of 15 tracked industries, lagging.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
- Industry rank
- #13 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on CORT?
HC Wainwright & Co. most recently reiterated its rating on Corcept Therapeutics Incorporated to Buy on Sep 18, 2026 with a price target of $165. Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- HC Wainwright & Co. — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
ETF holders
ETFs holding CORT
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▲ Buy | 12,432,023 | 11.14% | $1.08B | 2026-08-07 |
| Renaissance Technologies LLC | ▼ Sell | 5,261,628 | 4.71% | $457.50M | 2026-08-13 |
| Vanguard Group Inc | ▼ Sell | 9,494,822 | 8.51% | $330.42M | 2026-01-29 |
| FMR LLC (Fidelity) | ▲ Buy | 3,337,618 | 2.99% | $290.21M | 2026-08-13 |
| AQR Capital Management LLC | ▲ Buy | 2,582,561 | 2.31% | $224.55M | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 2,532,198 | 2.27% | $220.21M | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 1,137,559 | 1.02% | $98.91M | 2026-08-13 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 883,001 | 0.79% | $76.78M | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 753,796 | 0.68% | $65.54M | 2026-08-13 |
| Two Sigma Investments, LP | ▼ Sell | 610,078 | 0.55% | $53.05M | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 568,519 | 0.51% | $49.43M | 2026-08-14 |
| Invesco Ltd. | ▼ Sell | 523,669 | 0.47% | $45.53M | 2026-08-14 |
| Norges Bank | ▼ Sell | 487,055 | 0.44% | $42.35M | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 328,565 | 0.29% | $28.57M | 2026-08-14 |
| JPMorgan Chase & Co | ▲ Buy | 253,182 | 0.23% | $22.65M | 2026-08-12 |
| Millennium Management LLC | ▼ Sell | 152,567 | 0.14% | $13.27M | 2026-08-14 |
| Citigroup Inc | ▼ Sell | 141,809 | 0.13% | $12.33M | 2026-08-03 |
| Citadel Advisors LLC | ▼ Sell | 109,105 | 0.10% | $9.49M | 2026-09-02 |
| Prudential Financial Inc | ▲ Buy | 99,761 | 0.09% | $8.67M | 2026-08-12 |
| Voleon Capital Management LP | ▼ Sell | 91,926 | 0.08% | $7.99M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 164,074 | 0.15% | $6.61M | 2026-05-18 |
| Man Group plc | ▼ Sell | 71,491 | 0.06% | $6.22M | 2026-08-14 |
| Susquehanna International Group, LLP | ▼ Sell | 69,684 | 0.06% | $6.06M | 2026-08-14 |
| Gotham Asset Management, LLC | ▲ Buy | 60,181 | 0.05% | $5.23M | 2026-08-14 |
| Bridgewater Associates, LP | ▲ Buy | 57,602 | 0.05% | $5.01M | 2026-08-14 |